Medivation Inc. (NASDAQ:MDVN) traded up 19.7% during trading on Monday . The stock traded as high as $80.67 and last traded at $80.40, with a volume of 39,531,610 shares. The stock had previously closed at $67.16.

Several equities research analysts have recently commented on the stock. Wedbush reiterated a “buy” rating on shares of Medivation in a research report on Saturday, April 30th. Credit Suisse Group AG reiterated a “buy” rating and set a $49.00 price target on shares of Medivation in a research report on Sunday, May 1st. Barclays PLC reiterated a “buy” rating on shares of Medivation in a research report on Sunday, May 8th. Citigroup Inc. reiterated a “buy” rating on shares of Medivation in a research report on Sunday, June 26th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Medivation in a research report on Sunday, July 17th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Medivation currently has an average rating of “Hold” and a consensus price target of $72.99.

The stock has a 50 day moving average of $63.33 and a 200-day moving average of $52.09. The stock’s market cap is $13.34 billion.

Medivation (NASDAQ:MDVN) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. During the same period in the prior year, the company posted $0.58 EPS. The firm had revenue of $206 million for the quarter, compared to analyst estimates of $214.52 million. The business’s revenue for the quarter was up 17.4% compared to the same quarter last year. On average, equities research analysts anticipate that Medivation Inc. will post $1.28 EPS for the current fiscal year.

In other Medivation news, SVP Andrew Kenneth William Powell sold 2,578 shares of the stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $60.42, for a total transaction of $155,762.76. Following the completion of the sale, the senior vice president now owns 28,517 shares of the company’s stock, valued at approximately $1,722,997.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Other hedge funds recently made changes to their positions in the company. Schwab Charles Investment Management Inc. increased its stake in shares of Medivation by 12.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 349,297 shares of the biopharmaceutical company’s stock valued at $16,886,000 after buying an additional 38,893 shares during the period. BlackRock Advisors LLC increased its stake in shares of Medivation by 3.3% in the fourth quarter. BlackRock Advisors LLC now owns 1,245,350 shares of the biopharmaceutical company’s stock valued at $60,201,000 after buying an additional 40,001 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Medivation by 30.5% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,403,498 shares of the biopharmaceutical company’s stock valued at $67,845,000 after buying an additional 327,652 shares during the period. KBC Group NV increased its stake in shares of Medivation by 98.7% in the fourth quarter. KBC Group NV now owns 32,177 shares of the biopharmaceutical company’s stock valued at $1,556,000 after buying an additional 15,984 shares during the period. Finally, I.G. Investment Management LTD. increased its stake in shares of Medivation by 10.2% in the fourth quarter. I.G. Investment Management LTD. now owns 56,420 shares of the biopharmaceutical company’s stock valued at $2,727,000 after buying an additional 5,200 shares during the period.

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.